Agrégateur de contenus

angle-left Petr Kavan, MD, PhD

Chercheur associé, IR-CUSM,

Programme de recherche sur le cancer

Professeur agrégé

 

Mots-clés


Programme d'oncologie pour adolescents et jeunes adultes • cacner colorectal • tumeur cérébrale • carcinome hépatocellulaire

Aire de recherche


Ma recherche porte sur les cancers gastro-intestinal, hépatobiliaire et neurologique.

Publications choisies


  • Bevacizumab Plus Radiotherapy/Temozolomide for newly diagnosed Glioblastoma (AVAglio). Olivier L, Chinot MD, …..Petr Kavan, ….and Timothy Cloughesy. NEJM 2014

  • Bevacizumab use for recurrent high-grade glioma at McGill University Hospital. Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Kavan P,. Can J Neurol Sci 2013 Mar; 40(2): 241-6

  • Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shacham-Shmueli E, Buchbinder A, Goldberg RM. Cancer. 2013 Sep 16. doi: 10.1002/cncr.28358.

  • Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. Bouganim N, Mamo A, Wasserman DW, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P. Curr Oncol. 2013 Oct;20(5):247-51. doi: 10.3747/co.20.1370.

  • A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. Mamo A, Nogueira MC, Batist G, Palumbo M, Panasci L, Ferrario C, Chaudhury P, Metrakos P, Kavan P. Curr Oncol. 2013 Apr;20(2):e107-12. doi: 10.3747/co.20.1271.